Secondary Prevention following CABG: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation into Practice

摘要

BackgroundDespite evidence supporting the use of aspirin, B-blockers, ACE inhibitors, and lipid-lowering therapies in eligible patients, adoption of these secondary prevention measures following coronary artery bypass grafting (CABG) has been inconsistent. We sought to rigorously test on a national scale whether low-intensity continuous quality improvement (CQI) interventions can be used to speed secondary prevention adherence following CABG.